Dr. Reddy’s Laboratories has launched its ziprasidone mesylate 20 mg/mL for injection, the first generic version of Geodon (Pfizer) for injection, according to a company press release.1
The product is available in single-dose vials. Ziprasidone mesylate injection is an atypical antipsychotic indicated for the acute treatment of agitation in patients with schizophrenia for whom treatment with ziprasidone is appropriate and who need intramuscular antipsychotic medication.2
According to the prescribing information, prescribers should be aware of the capacity of ziprasidone mesylate for injection to prolong the QT interval and may consider the use of other treatments first. The medication contains a warning for increased mortality in older patients with dementia-related psychosis.2
“We’re pleased to bring the first generic of ziprasidone mesylate for injection to market for patients who will benefit from access to affordable medicine,” Marc Kikuchi, chief executive officer, North America Generics, Dr. Reddy’s Laboratories, said in a statement.1 “With every new product launch, we believe we are making health care more affordable by delivering the value to the pharmacy. This is a great addition to our injectable offering in the US market as we continue to augment our portfolio and drive growth within the hospital segment.”
1. Dr. Reddy’s Laboratories announces the launch of ziprasidone mesylate for injection in the US market [news release]. Dr. Reddy’s website. https://www.drreddys.com/media/854785/press-release_ziprasidone-mesylate-for-injection.pdf. Accessed March 18, 2020.
2. Ziprasidone 20 mg. Prescribing Information. Dr. Reddy’s Laboratories. https://www.drreddys.com/pi/ziprasidone-20mg.pdf. Accessed March 18, 2020.